Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.48 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.45 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16156180 | 0.88 | PTGDR2 (0.47) | PTGDR2CCR2AKR1B1PTGIRPTGDR | |
| SCHEMBL12371073 | 0.88 | KDM4E (0.45) | KDM4EALDH1A1HPGDHSD17B10CCR2 | |
| SCHEMBL3005494 | 0.84 | PTGDR2 (0.47) | KDM4EALDH1A1PTGDR2AKR1B1 | |
| SCHEMBL1422093 | 0.84 | ALDH1A1 (0.55) | KDM4EALDH1A1HPGDHSD17B10PRMT5 | |
| SCHEMBL1598783 | 0.82 | ALDH1A1 (0.56) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1251025 | 0.81 | CCR2 (0.47) | KDM4EALDH1A1CCR2 | |
| SCHEMBL1467597 | 0.81 | CCR2 (0.54) | PTGDR2CCR2AKR1B1 | |
| SCHEMBL23502112 | 0.81 | KDM4E (0.38) | KDM4EHSD17B10PTGDR2 | |
| SCHEMBL27990361 | 0.81 | CCR2 (0.50) | PTGDR2CCR2AKR1B1 | |
| SCHEMBL21031894 | 0.80 | CACNA1B (0.46) | KDM4EALDH1A1HPGDHSD17B10CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| EP-1551802-B1 | INDOLE-3-SULPHUR DERIVATIVES | ASTRAZENECA AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| CN-101506159-A | Compounds having CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
| WO-2009090414-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| CN-101454284-A | Biaryl or aryl-heteroaryl substituted indoles | ASTRAZENECA AB (SE) | 2009-06-10 | — | — | CN | disclosed |
| US-20090143449-A1 | Bi-Aryl or Aryl-Heteroaryl Substituted Indoles | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| EP-2046740-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012511-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| CN-1279023-C | Indole-3-sulphur derivatives | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | CN | disclosed |
| US-20060111426-A1 | Indole-3-sulphur derivaties | ASTRAZENECA AB (SE) | 2006-05-25 | — | — | US | disclosed |
| CN-1678579-A | Indole-3-sulfur derivatives | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
| US-20090143449-A1 | Bi-Aryl or Aryl-Heteroaryl Substituted Indoles | AHR, IDO1, IDO2 | KDM4E 2290/4885ALDH1A1 142/4885HPGD 692/4885 |
| US-20060111426-A1 | Indole-3-sulphur derivaties | IDO1, IDO2, INMT | KDM4E 2224/4885ALDH1A1 290/4885HPGD 647/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | KDM4E 1590/4885ALDH1A1 649/4885HPGD 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.